XML 60 R26.htm IDEA: XBRL DOCUMENT
v3.2.0.727

COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) - USD ($) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 02, 2014 | Jun. 29, 2015 | Apr. 30, 2013 | Jul. 17, 2012 | Jun. 30, 2015 | Jun. 30, 2015 | Jul. 31, 2015 | Sep. 30, 2013 | Sep. 25, 2013
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Granted |  |  |  |  |  | 103,025 |  |  |
Initial Public Offering |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Net offering proceeds |  | $ 17,400,000 |  |  |  |  |  |  |
FDA Meeting Bonus Opportunities | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  |  | $ 10,000 |  |  |  |  |  |
FDA Meeting Bonus Opportunities | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  |  | $ 10,000 |  |  |  |  |  |
Clinical Trial Funding Commitment Bonus Opportunities | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  | 75,000 |  |  |  |  |  |  |
Clinical Trial Funding Commitment Bonus Opportunities | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  | 75,000 |  |  |  |  |  |  |
Clinical Trial Funding Commitment Bonus Opportunities | General and administrative expense | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Accrued bonus to executive |  |  |  |  | $ 75,000 | $ 75,000 |  |  |
Clinical Trial Funding Commitment Bonus Opportunities | General and administrative expense | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Accrued bonus to executive |  |  |  |  | 75,000 | 75,000 |  |  |
Clinical Trial Funding Commitment Bonus Opportunities | Minimum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Minimum cash available limit |  | $ 2,000,000 |  |  |  |  |  |  |
Fundraising Bonus Opportunities | General and administrative expense | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Accrued bonus to executive |  |  |  |  | 150,000 | 150,000 |  |  |
Fundraising Bonus Opportunities | General and administrative expense | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Accrued bonus to executive |  |  |  |  | $ 150,000 | $ 150,000 |  |  |
Fundraising Bonus Opportunities | Performance milestone condition one |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  |  |  | $ 50,000 |  |  |  |  |
Minimum actual deployment of funds by third party |  |  |  | 2,000,000 |  |  |  |  |
Fundraising Bonus Opportunities | Performance milestone condition one | Minimum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Minimum cash available limit |  |  |  | 2,000,000 |  |  |  |  |
Fundraising Bonus Opportunities | Performance milestone condition two |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Minimum actual deployment of funds by third party |  |  |  | 10,000,000 |  |  |  |  |
Fundraising Bonus Opportunities | Performance milestone condition two | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  |  |  | 150,000 |  |  |  |  |
Fundraising Bonus Opportunities | Performance milestone condition two | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Cash bonus |  |  |  | 150,000 |  |  |  |  |
Fundraising Bonus Opportunities | Performance milestone condition two | Minimum |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Minimum cash available limit |  |  |  | $ 2,000,000 |  |  |  |  |
Executive Options | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Granted | 453,413 |  |  |  |  |  |  |  |
Executive Options | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Granted | 453,413 |  |  |  |  |  |  |  |
Executive Options | FDA Meeting Bonus Opportunities | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  |  |  |  |  |  |  | 1,136 | 2,360
Executive Options | FDA Meeting Bonus Opportunities | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  |  |  |  |  |  |  | 1,136 | 2,360
Executive Options | Clinical Trial Funding Commitment Bonus Opportunities |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stock options to vest ratably on a monthly basis |  | 6,818 |  |  |  |  |  |  |
Percentage of option vest |  | 35.00% |  |  |  |  |  |  |
Granted |  | 10,489 |  |  |  |  |  |  |
Vesting period of options |  | 36 months |  |  |  |  |  |  |
Executive Options | Clinical Trial Funding Commitment Bonus Opportunities | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  | 3,671 |  |  |  |  |  |  |
Executive Options | Clinical Trial Funding Commitment Bonus Opportunities | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  | 3,671 |  |  |  |  |  |  |
Executive Options | Fundraising Bonus Opportunities | Initial Public Offering |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Net offering proceeds |  | $ 17,400,000 |  |  |  |  |  |  |
Executive Options | Fundraising Bonus Opportunities | Subsequent Event |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  |  |  |  |  |  | 9,091 |  |
Executive Options | Fundraising Bonus Opportunities | Performance milestone condition one |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Percentage of option vest |  |  |  | 35.00% |  |  |  |  |
Granted |  |  |  | 6,993 |  |  |  |  |
Maximum aggregate number of shares of common stock authorized to issue |  |  |  | 6,993 |  |  |  |  |
Vesting period of options |  |  |  | 36 months |  |  |  |  |
Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Percentage of option vest |  |  |  | 35.00% |  |  |  |  |
Granted |  |  |  | 13,986 |  |  |  |  |
Maximum aggregate number of shares of common stock authorized to issue |  |  |  | 13,986 |  |  |  |  |
Vesting period of options |  |  |  | 36 months |  |  |  |  |
Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two | Andrew Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  | 4,895 |  |  |  |  |  |  |
Executive Options | Fundraising Bonus Opportunities | Performance milestone condition two | Ira Ritter |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of stock options expected to vest |  | 4,895 |  |  |  |  |  |  |

X
- Definition Represents amount of accrued bonus to executive. + References No definition available. + Details
Name: | rttr_AccruedBonusToExecutive
Namespace Prefix: | rttr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | rttr_CommitmentsAndContingenciesLineItems
Namespace Prefix: | rttr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents executive compensation payable upon satisfaction of condition. + References No definition available. + Details
Name: | rttr_ExecutiveCompensation
Namespace Prefix: | rttr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents minimum actual deployment of funds by third party. + References No definition available. + Details
Name: | rttr_MinimumActualDeploymentOfFundsByThirdParty
Namespace Prefix: | rttr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents number of share options vests ratably on a monthly basis. + References No definition available. + Details
Name: | rttr_StockOptionsToVestRatablyOnMonthlyBasis
Namespace Prefix: | rttr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of vesting of share-based compensation awards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FdaMeetingBonusOpportunitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=rttr_PresidentAndFormerChiefExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=rttr_ChiefStrategicOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_ClinicalTrialFundingCommitmentBonusOpportunitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rttr_CashBonusAndExecutiveOptionsPerformanceConditionsAxis=rttr_FundraisingBonusOpportunitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rttr_PerformanceMilestoneTypeAxis=rttr_PerformanceMilestoneConditionTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |